지아이이노베이션

358570KOSDAQ자연과학 및 공학 연구개발업

53.5 / 100

Reference Date: 2026-04-13

Financial Score21.0 / 40

News Sentiment16.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly down 2.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GI Innovation is a biotechnology company specializing in the development of next-generation immune therapies based on fusion proteins, with key drug pipelines including GI-101, GI-102, GI-301, and GI-108. The company utilizes its proprietary GI-SMART™ platform technology to rapidly develop novel bispecific fusion proteins and has achieved growth through technology transfer collaborations with global partners.

Number of Employees

82people

Average Salary

131.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

7.66Industry Average 3.820.0Point

2.0x industry avg (risky)

ROE

-48.28Industry Average -32.113.5Point

1.5x industry avg (good)

Debt Ratio

1.47Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲11921.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -77.1% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 0Negative 0Average Sentiment Score 90

Positive
지아이이노베이션, 존슨앤존슨과 전립선암 병용요법 임상공급 계약
지아이이노베이션은 존슨앤존슨과 전이성 거세저항성 전립선암 병용요법 개발을 위한 임상공급 계약을 체결했습니다.
Positive
지아이이노, J&J와 전립선암 병용요법 치료 가능성 탐색
지아이이노베이션은 존슨앤존슨과 전립선암 환자를 대상으로 면역항암제 GI-102와 T세포 인게이저 파스리타미그 병용요법의 치료 가능성을 탐색하는 임상공급 계약을 체결했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 13,900Won52-week high 24,00052-week low 11,610

1-month return2.0Point

1m -2.11% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral주식매수선택권부여에관한신고2026-03-27
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제 1b/2상 임상시험계획 승인 신청)2026-03-19